The study provides the clearest evidence yet that medicines like BIIB080 might improve cognition, but leaves unclear why higher doses didn’t perform better.
Source: BioPharma Dive
You may also like
EC approves Erbitux combination for first‑line...
FDA approves Leqembi Iqlik subcutaneous initiation...
AstraZeneca agrees on $1.5bn deal with Dizal...
Cherry appoints Peter Henshaw as new Managing Director
Novel Epigenetic Therapy Targets Treatment-Resistant...
FDA Issues Proposal to Streamline Registration for...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.